News | May 08, 2007

Favorable Results Presented on Edwards’ Mitral Valve Repair Ring

May 9, 2007 — Edwards Lifesciences Corp., a global developer of heart valves, has announced the first clinical study results of the recently introduced Edwards Myxo ETlogix annuloplasty ring. The study results showed that the ring, designed specifically to treat patients with myxomatous disease, reduced mitral regurgitation (MR) in patients who underwent the surgery to repair their diseased mitral valves.

According to the study results for Myxo ETlogix annuloplasty Ring, surgical treatment of myxomatous (Myxo) mitral disease with the Edwards Myxo ETlogix annuloplasty ring reduces MR. The repair technique also simplified what is typically an intricate surgical procedure.

The clinical study presentation, titled “Novel Surgical Approach to Myxomatous Mitral Valve Repair,” will be presented at the 87th annual meeting of the American Association for Thoracic Surgery (AATS) in Washington, D.C., today by Patrick McCarthy, M.D. Dr. McCarthy is the chief of the division of cardiothoracic surgery at Northwestern Memorial Hospital in Chicago and also serves as co-director of Northwestern Memorial’s Bluhm Cardiovascular Institute. McCarthy is also a Heller-Sacks professor of surgery at Northwestern University’s Feinberg School of Medicine, as well as a paid consultant to Edwards Lifesciences.

Additionally, the company announced the European launch of its Carpentier-Edwards PERIMOUNT Magna Ease aortic valve to complement its robust tissue valve product line.

The Carpentier-Edwards PERIMOUNT Magna Ease aortic valve, the newest addition to Edwards’ industry-leading tissue valve line, adds improved ease of use to the excellent hemodynamic performance of the Magna valve platform. The Magna Ease valve is built on the proven performance of PERIMOUNT valves, with long-term durability of up to 20 years.

The lower profile of the Carpentier-Edwards PERIMOUNT Magna Ease aortic valve offers easier insertion through small incisions or in small aortic roots and also provides a better option in treating patients with irregular or challenging anatomies. The product has received CE Mark approval for Europe, but it is not available for sale in the U.S.

For more information visit www.edwards.com.

Related Content

Second Micro Interventional Devices Annuloplasty System Successfully Implanted
News | Annuloplasty Rings| October 30, 2017
Micro Interventional Devices Inc. (MID) recently announced the second successful implantation of its MIA (Minimally...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings| July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings| July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign Percutaneous Annuloplasty System, MPAS, CE Mark approval
News | Annuloplasty Rings| April 27, 2016
Mitralign Inc. announced its Mitralign Percutaneous Annuloplasty System (MPAS) has received CE mark approval from its...
Carillon mitral contour system, Cardiac Dimensions, functional mitral regurgitation, FMR, University Hospital Liepzig study
News | Annuloplasty Rings| February 24, 2016
A single-center study noted that treatment with Cardiac Dimensions’ Carillon Mitral Contour System resulted in...
Carillon mitral contour system, cost-effective, optimal medical treatment, OMT, TITAN, functional mitral regurgitation, FMR

Carillon mitral contour system image courtesy of Cardiac Dimensions Inc.

News | Annuloplasty Rings| September 10, 2015
The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical...
Overlay Init